{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:03Z","timestamp":1791389883178,"version":"4.3.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jtho.2021.06.022","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:29:38Z","timestamp":1625570978000},"page":"1582-1588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC"],"prefix":"10.1016","volume":"16","author":[{"given":"Christine L.","family":"Hann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina M.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrianne","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maulik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Nimeiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Komarnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.06.022_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtho.2021.06.022_bib2","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.06.022_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2021.06.022_bib4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.06.022_bib5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.06.022_bib6","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A\u00a0DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in\u00a0vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2021.06.022_bib7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/hmg\/ddq529","article-title":"Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis","volume":"20","author":"Chapman","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jtho.2021.06.022_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.06.022_bib9","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.06.022_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2019.07.025","article-title":"Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer","volume":"135","author":"Udagawa","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.06.022_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment of extensive-stage small cell lung carcinoma: current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2021.06.022_bib12","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.06.022_bib13","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","article-title":"A phase 1\u20132 study\u00a0of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC","volume":"16","author":"Malhotra","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"suppl 12","key":"10.1016\/j.jtho.2021.06.022_bib16","article-title":"HPN328: an anti-DLL3 T cell engager for treatment of small cell lung\u00a0cancer","volume":"18","author":"Aaron","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"suppl 15","key":"10.1016\/j.jtho.2021.06.022_bib17","article-title":"Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC)","volume":"37","author":"Smit","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421022899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421022899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:46:52Z","timestamp":1761562012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421022899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1556086421022899"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.06.022","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}